Open-label Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of Ustekinumab in Pediatric Participants
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Ustekinumab (Primary)
- Indications Juvenile rheumatoid arthritis; Psoriasis
- Focus Pharmacokinetics
- Acronyms U-POPS
- Sponsors Janssen Research & Development
Most Recent Events
- 28 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 Dec 2023 Planned End Date changed from 24 Jan 2024 to 2 Feb 2024.
- 07 Nov 2023 Status changed from recruiting to active, no longer recruiting.